Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05780437 · ClinicalTrials.gov registry record · Phase 3
AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,455
- Enrollment target
NCT05780437: Completed Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT05780437 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,455 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05780437, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,455 participants
- Enrollment target
Study Summary
This study looks at the safety and effectiveness of AZD7442 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a AZD7442 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H4.
Primary Outcome
The primary endpoint is the proportion of subjects with sustained recovery, which is defined as being discharged from the index hospitalization, followed by being alive and home for 14 consecutive days prior to Day 90. Home is defined as the level of residence or facility where the participant was residing prior to hospital admission leading to enrollment in this protocol. Readmission from "home" may occur, and if this occurs within 14 days of the first discharge to "home," then the primary endp
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Remdesivir
- BIOLOGICAL AZD7442
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,455 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2023-06-09 |
| Phase | Phase 3 |
What the finished NCT05780437 record still lists
NCT05780437 is an interventional study that assigns participants to a tested intervention. Its 1,455 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05780437 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05780437 about?
NCT05780437 is a clinical study titled "AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)". This study looks at the safety and effectiveness of AZD7442 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a AZD7442 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatm...
What is the current status of trial NCT05780437?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,455 participants. The study started on 2021-02-10. Estimated completion is 2023-06-09.
What interventions are being tested in trial NCT05780437?
The interventions under investigation include: Placebo (BIOLOGICAL), Remdesivir (BIOLOGICAL), AZD7442 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05780437?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05780437's enrollment target sits among peer trials
1,455 166th of 2000 higher than 1,835 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI